TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
TRACON Pharmaceuticals (Nasdaq: TCON) announced that Charles Theuer, M.D., Ph.D., its President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 11:00 am ET. The event aims to showcase TRACON's innovative cancer therapeutics and its CRO-independent development platform. Key products include Envafolimab, YH001, TRC102, and TJ004309, which target various types of cancer. For further details, visit TRACON's website.
- None.
- None.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 11:00 am Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue share partnership, or through franchising TRACON’s product development platform by licensing TRACON’s clinical know-how. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
What event will TRACON Pharmaceuticals participate in on June 10, 2022?
Who will represent TRACON Pharmaceuticals at the Jefferies Healthcare Conference?
What is the focus of TRACON Pharmaceuticals?
Which cancer therapeutics are included in TRACON's pipeline?
Where can I watch TRACON Pharmaceuticals' presentation from the Jefferies Conference?
